Skip to main content
TipRanks
Go Ultimate75% OFF

Guided Therapeutics (GTHP) Ratios

29 Followers

Guided Therapeutics Ratios

GTHP's free cash flow for Q2 2026 was $-319.00K. For the 2026 fiscal year, GTHP's free cash flow was increased by $0.00 and operating cash flow was $-319.00K. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio0.090.190.290.620.29
Quick Ratio0.020.090.160.500.19
Cash Ratio0.010.060.120.480.11
Solvency Ratio-0.42-0.37-0.62-0.68-0.28
Operating Cash Flow Ratio-0.16-0.18-0.36-0.30-0.28
Short-Term Operating Cash Flow Coverage-0.49-0.58-1.34-1.83-1.40
Net Current Asset Value$ -6.72M$ -5.07M$ -4.08M$ -3.25M$ -5.85M
Leverage Ratios
Debt-to-Assets Ratio2.221.571.230.671.42
Debt-to-Equity Ratio-0.49-0.44-0.54-0.78-0.53
Debt-to-Capital Ratio-0.96-0.79-1.18-3.65-1.14
Long-Term Debt-to-Capital Ratio-0.01-0.01-0.16-0.64-0.34
Financial Leverage Ratio-0.22-0.28-0.44-1.17-0.37
Debt Service Coverage Ratio-0.88-0.84-1.98-2.65-0.40
Interest Coverage Ratio-3.84-5.53-12.44-5.73-2.05
Debt to Market Cap0.050.230.230.200.32
Interest Debt Per Share0.050.040.050.090.30
Net Debt to EBITDA-1.16-0.91-0.470.01-2.45
Profitability Margins
Gross Profit Margin74.45%28.57%36.73%-523.08%24.69%
EBIT Margin-336.25%-29085.71%-3276.53%-28915.38%-1135.80%
EBITDA Margin-322.29%-27728.57%-3189.80%-28361.54%-1134.57%
Operating Profit Margin-309.26%-30114.29%-3527.55%-25638.46%-2916.05%
Pretax Profit Margin-416.69%-34528.57%-3560.20%-33392.31%-2555.56%
Net Profit Margin-416.69%-34528.57%-3560.20%-33392.31%-2555.56%
Continuous Operations Profit Margin-416.69%-34528.57%-3560.20%-33392.31%-2555.56%
Net Income Per EBT100.00%100.00%100.00%100.00%100.00%
EBT Per EBIT134.74%114.66%100.93%130.24%87.64%
Return on Assets (ROA)-241.39%-175.40%-209.05%-128.97%-101.47%
Return on Equity (ROE)53.21%49.44%91.67%150.57%38.02%
Return on Capital Employed (ROCE)44.65%44.13%110.10%221.76%64.64%
Return on Invested Capital (ROIC)77.34%77.22%197.77%541.95%96.53%
Return on Tangible Assets-241.39%-175.40%-209.05%-128.97%-101.47%
Earnings Yield-7.55%-28.10%-44.45%-44.52%-26.68%
Efficiency Ratios
Receivables Turnover191.752.3314.002.171.76
Payables Turnover0.080.000.030.040.02
Inventory Turnover0.440.010.100.150.11
Fixed Asset Turnover1.090.040.380.040.21
Asset Turnover0.580.010.060.000.04
Working Capital Turnover Ratio-0.14-0.00-0.04-0.00-0.01
Cash Conversion Cycle-3720.72-109124.57-8162.88-7388.39-11029.93
Days of Sales Outstanding1.90156.4326.07168.46207.28
Days of Inventory Outstanding834.2946209.003720.652469.383416.64
Days of Payables Outstanding4556.91155490.0011909.6010026.2314653.85
Operating Cycle836.1946365.433746.722637.843623.92
Cash Flow Ratios
Operating Cash Flow Per Share-0.01-0.02-0.03-0.05-0.12
Free Cash Flow Per Share-0.01-0.02-0.03-0.05-0.12
Dividend Paid and CapEx Coverage Ratio-7.03-6.430.00-47.68-113.71
Capital Expenditure Coverage Ratio-534.000.000.00-47.68-113.71
Operating Cash Flow Coverage Ratio-0.36-0.52-0.85-0.65-0.55
Operating Cash Flow to Sales Ratio-1.39-159.86-17.82-113.69-19.65
Free Cash Flow Yield-2.53%-13.01%-22.25%-15.47%-20.70%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-12.65-3.32-2.25-2.25-3.75
Price-to-Sales (P/S) Ratio55.211228.6980.09750.1295.79
Price-to-Book (P/B) Ratio-7.05-1.76-2.06-3.38-1.42
Price-to-Free Cash Flow (P/FCF) Ratio-39.57-7.69-4.50-6.46-4.83
Price-to-Operating Cash Flow Ratio-39.65-7.69-4.50-6.60-4.87
Price-to-Earnings Growth (PEG) Ratio2.290.090.040.13-0.01
Enterprise Value Multiple-18.29-5.34-2.98-2.63-10.90
Enterprise Value45.22M10.37M9.32M9.70M10.01M
EV to EBITDA-18.29-5.34-2.98-2.63-10.90
EV to Sales58.961481.6995.06746.27123.64
EV to Free Cash Flow-42.26-9.27-5.34-6.43-6.24
EV to Operating Cash Flow-42.34-9.27-5.34-6.56-6.29
Tangible Book Value Per Share-0.08-0.09-0.07-0.09-0.41
Shareholders’ Equity Per Share-0.08-0.09-0.07-0.09-0.41
Tax and Other Ratios
Effective Tax Rate0.000.000.000.000.00
Revenue Per Share0.010.000.000.000.01
Net Income Per Share-0.04-0.04-0.07-0.13-0.15
Tax Burden1.001.001.001.001.00
Interest Burden1.241.191.091.152.25
Research & Development to Revenue0.6175.142.335.920.85
SG&A to Revenue3.23226.2930.58231.3126.81
Stock-Based Compensation to Revenue0.4917.1418.43106.232.81
Income Quality0.330.460.500.340.77

Currency in USD